NCT05385770 - Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects | Biotech Hunter

Enrollment

890

Participants

Timeline

Start Date

July 8, 2022

Primary Completion Date

July 11, 2024

Study Completion Date

July 19, 2024

Conditions

Essential Hypertension

Interventions

DRUG

AZM X mg + AML Y mg

tablet, single dose, QD, oral administration

DRUG

AZM X mg + AML Y' mg

tablet, single dose, QD, oral administration

DRUG

AZM X' mg + AML Y mg

tablet, single dose, QD, oral administration

DRUG

AZM X' mg + AML Y' mg

tablet, single dose, QD, oral administration

DRUG

AZM X mg

tablet, single dose, QD, oral administration

DRUG

AZM X' mg

tablet, single dose, QD, oral administration

DRUG

AML Y mg

tablet, single dose, QD, oral administration

DRUG

AML Y' mg

tablet, single dose, QD, oral administration

Trial Locations (1)

Celltrion, Incheon